Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinically stable persistent mild/moderate asthma within the 4 weeks preceding the screening visit,
screening pre-bronchodilator FEV1 \>or=60 % predicted,demonstrate the presence of reversible airway disease, defined as an increase in FEV1 of \>or= 12.0% over the max of the three screening measures and an absolute change of
\>or= 200 mL within 30 minutes following a single 400 mcg salbutamol dose, male or female (of non child bearing potential or meet the contraception criteria),
BMI 19-31 kg/m2,
Non-smoker,
refrains from use of prohibited medication within the specified timeframes
You may not be if
Pregnant or nursing females
History of life threatening asthma
Subjects who are unable to stop taking protocol defined prohibited medication
Clareo Health | Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.
